The Client
Adams Clinical is a contract research organization (CRO) specializing in psychiatric and neurological medicine studies. They run clinical trials for conditions including Alzheimer's disease, depression, and anxiety across multiple US trial sites.
Clinical trial recruitment is one of the hardest problems in healthcare marketing. The target audience is patients who may not know they qualify for a trial, may not know trials exist, and in many cases may carry stigma around their condition that makes them unlikely to engage with an ad. Every piece of creative requires IRB (Institutional Review Board) approval before it can run. And the funnel from ad click to enrolled patient has more friction points than almost any other paid media use case.
Adams Clinical came to Brighter Click in August 2023 with a single marketing manager running their entire paid media operation. They were managing six active trials across three cities, spending $360,000 per month on Facebook ads, and struggling to make the creative work.
The Problem
Three problems were compounding on each other.
The creative lacked diversity and depth. Adams Clinical was running ads that did not provide enough information to convert their target audience. Clinical trial advertising is unlike any other category. You are not selling a product. You are asking someone to consider participating in a medical study for a condition they may not have told anyone about. The existing ads were not meeting patients where they were emotionally or informationally.
Both lead volume and lead quality were suffering. The enrollment funnel for a clinical trial runs from ad click to Facebook form fill to CRM to outbound call center contact. At $360K per month in ad spend, the volume of leads coming through the top of that funnel was not sufficient, and the leads that did come through were not converting to qualified trial candidates at an acceptable rate. A lead who fills out a form but does not qualify for the study or does not answer the phone when the call center follows up is a wasted impression and a wasted dollar.
The scale of the operation demanded a specialized partner. Six simultaneous trials. Three cities. Hyperlocal geographic targeting around each trial site using specific zip codes. Condition-specific creative that needed to be tested, iterated, and approved through IRB for every variation. A single marketing manager could not manage the creative strategy, media buying, performance analysis, and IRB coordination required at this budget level.
The Strategy
The Creative Strategy Framework
Clinical trial advertising has a unique challenge that most consumer brands never face: the conditions you are recruiting for have seasonality, but it is not the seasonality of retail. Depression and anxiety have seasonal patterns tied to life events, weather, and cultural cycles. Alzheimer's awareness spikes around specific months. The urgency a patient feels about seeking treatment fluctuates based on whether their symptoms are active or dormant.
We built a creative strategy framework around four core motivators, each with distinct messaging angles and creative themes:
1. Hope. Messaging focused on the possibility of new treatments: "Discover possible treatments for [condition] by participating in a clinical trial." Creative execution: static images with bold text overlays and clean medical imagery. This angle appeals to patients who have tried existing treatments without success and are looking for new options.
2. Symptoms. Messaging that leads with the patient's lived experience rather than the trial itself. Two approaches: single-symptom ads that isolate one recognizable experience ("Trouble with familiar tasks," "Frequent low mood and sadness," "Excessive worrying") and multi-symptom ads that list several indicators. Creative execution: quiz-style imagery, illustrated symptom representations, and photographic depictions of specific symptoms. This angle performs well because it meets patients in their experience before asking them to consider a clinical trial.
3. Memory Loss. A dedicated messaging category for Alzheimer's recruitment that applies the above motivators specifically through the lens of memory loss rather than using the clinical term "Alzheimer's." This distinction matters enormously. Our all-time data shows that "memory loss" messaging delivers leads at $27.96 CPL, making it the single most effective messaging angle across all conditions and all trials. Patients and their families recognize and respond to "memory loss" as a description of their experience. "Alzheimer's" can feel clinical, intimidating, or premature for someone who has not yet received a formal diagnosis.
4. Availability. Messaging that emphasizes access and timing: "Did you know paid clinical trials are available?", "New studies beginning soon in [city]." Creative execution: grid layouts showing multiple trial options and video adaptations of top-performing static ads. This angle captures patients who are already aware of their condition and open to participating but did not know local trials existed.
Condition-Specific Creative by Trial
Each condition required its own creative approach because the patient psychology is fundamentally different.
Alzheimer's/Memory Loss trials target both patients and their caregivers (often family members). The top-performing Alzheimer's ads use grid-style layouts showing relatable daily symptoms (forgetting appointments, needing to write everything down, repeating questions, misplacing things) alongside imagery of older adults in familiar settings. City-specific callouts ("Paid Memory Loss Studies in Boston") drove strong performance by making the opportunity feel local and accessible. Our best-performing Alzheimer's ad achieved a $1,400 cost per anonymized patient.
Depression trials require creative that acknowledges the condition without reinforcing hopelessness. Our top-performing depression ads balance symptom recognition with a path forward. Localized callouts ("Depression Clinical Research in NYC") combined with specific symptom language ("Frequent low mood and sadness," "Insomnia") and a clear offer of possible treatment through trial participation. Illustrated creative, including hand-drawn style imagery depicting emotional states, consistently outperformed stock photography for depression trials. Our best depression ad achieved a $1,750 cost per anonymized patient.
Anxiety trials responded best to creative that validates the patient's experience. Ads naming specific anxiety symptoms ("Excessive worrying," "Racing thoughts, restlessness, difficulty sleeping") paired with direct city callouts ("Paid Anxiety Studies - Boston") and the straightforward CTA of discovering possible treatments through a clinical trial. Both photographic and illustrated creative styles performed well for anxiety, with our top performer delivering a $780 cost per anonymized patient.
The IRB Workflow
Every ad in a clinical trial account requires IRB approval before it can run. This is a regulatory requirement with no shortcuts. Where most agencies treat IRB as a bottleneck that slows everything down, we built it into our creative production cycle. We batch creative submissions, plan briefs far enough in advance to absorb approval timelines, and design ads in modular formats so that when one element needs revision for compliance, we do not have to rebuild the entire ad from scratch.
Format Innovation: Static to GIF to Video
One of our most effective creative strategies was an iterative format pipeline. We start with static ads because they are fastest to produce and get through IRB. Once we identify a static that performs, we convert it into a GIF that adds subtle motion (symptom text animating in, images transitioning). Our all-time data shows video delivers the lowest CPL at $38.40, followed closely by GIF at $39.49, with static at $41.63. The difference is small enough that the speed advantage of static for initial testing is worth it, and the format pipeline ensures every winning concept eventually gets produced in the highest-performing format.
The Results
45.9% decrease in cost per lead. Across all trials and all conditions, we cut CPL by nearly half through creative diversification, structured messaging testing, and format optimization.
91.5% increase in click-to-conversion ratio. The percentage of people who clicked an ad and completed the Facebook lead form nearly doubled. This was driven by creative that provided enough information upfront so that the people clicking were genuinely interested in learning about the trial, not just curiosity clicks from vague or misleading ads.
Ad spend scaled from $360K to $600K per month. As performance improved, Adams Clinical increased investment. Budget grew 67% over the course of the engagement because the unit economics justified it. More spend at a lower CPL means more qualified candidates entering the recruitment pipeline.
Ongoing engagement. Adams Clinical has been with Brighter Click for over a year and continues to expand the scope of the partnership as new trials launch. In a category where pharmaceutical sponsors measure CRO performance by enrollment speed, having a reliable paid media partner that consistently delivers qualified candidates on budget is a competitive advantage for the CRO itself.
What We Learned
The all-time creative performance data from this account reveals patterns that apply to clinical trial recruitment broadly:
Lead with the patient's language, not the clinical language. "Memory loss" at $27.96 CPL dramatically outperforms every other messaging angle. Patients describe their experience in everyday terms. Ads should mirror that language.
Symptom-specific creative outperforms general condition creative. Across all three primary conditions (Alzheimer's, depression, anxiety), the top-performing ads isolate specific, recognizable symptoms rather than naming the condition in the headline. A person scrolling Facebook is more likely to stop for "Trouble with familiar tasks" than "Alzheimer's Clinical Trial Available."
City callouts drive performance. Ads that name the specific city ("Boston Anxiety Clinical Trials," "Depression Clinical Research in NYC," "Paid Memory Loss Studies in Boston") consistently outperform ads with generic geographic language. The patient needs to know this opportunity is physically near them.
Illustrated creative has a role. For depression and anxiety trials, illustrated and hand-drawn creative styles perform as well as or better than stock photography. The stylized approach allows the creative to convey emotional states without relying on stock imagery that can feel generic or exploitative.
Format matters less than message, but video edges out. Video, GIF, and static all perform within a narrow CPL range ($38 to $42). The takeaway is that format alone is not the lever. The message, the symptom specificity, and the local relevance of the ad matter more than whether it moves or not. That said, converting proven static concepts into video format reliably squeezes an additional 5 to 8% efficiency.
Why This Worked
Clinical trial recruitment is not a category where you can run generic awareness ads and hope for the best. Every dollar wasted on a lead that does not qualify for the study is a dollar that did not help enroll a patient who needs treatment.
We built a creative strategy framework specifically for this challenge: motivator-based messaging (hope, symptoms, memory loss, availability) mapped to condition-specific creative themes and iterated through a format pipeline (static to GIF to video) that maximizes speed to market while continuously improving performance.
The result is a system that gets more niche and more effective the longer it runs. Every month of data makes the next month's creative briefs sharper. Every new trial launch benefits from the messaging and format insights accumulated across all previous trials. That compounding intelligence is what allowed us to cut CPL by nearly half while scaling spend from $360K to $600K per month.
For a CRO, faster and cheaper patient enrollment is the single most valuable outcome a marketing partner can deliver. It means meeting sponsor timelines. It means winning more trial contracts. It means more patients getting access to treatments that could change their lives.
.png)
.jpg)
